HealthEquity stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 68 to 73.
When To Sell Stocks To Lock In Profits And Minimize Losses
This proprietary rating measures technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History shows that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 in the early stages of their moves. See if HealthEquity stock can continue to show renewed price strength and clear that threshold.
Is HealthEquity Stock A Buy?
HealthEquity stock has since pulled back from its June 4 breakout from a cup-with-handle pattern. It's not currently offering a proper buying opportunity. See if the stock goes on to form a sound pattern that could ignite a new run.
While revenue growth fell last quarter from 19% to 15%, EPS grew 21%, up from 10% in the previous report.
HealthEquity stock holds the No. 2 rank among its peers in the Commercial Services-Outsourcing industry group. Aramark is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
